FDA launches framework to close a rare-disease treatment gap affecting 30 million Americans
Only about 5% of recognised rare diseases have an approved treatment. The agency says it will adapt how it weighs evidence for small patient populations, while keeping its core safety and effectiveness standard intact.
3 min read